Literature DB >> 9018122

Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53.

F Kashanchi1, J Araujo, J Doniger, S Muralidhar, R Hoch, S Khleif, E Mendelson, J Thompson, N Azumi, J N Brady, M Luppi, G Torelli, L J Rosenthal.   

Abstract

The 357 amino acid open reading frame 1 (ORF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication (Kashanchi et al., Virology, 201, 95-106, 1994). In the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment. Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV. Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic. Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the ORF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated ORF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed ORF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of ORF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that ORF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018122     DOI: 10.1038/sj.onc.1200840

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Expression of human herpesvirus-6 antigens in benign and malignant lymphoproliferative diseases.

Authors:  M Luppi; P Barozzi; R Garber; A Maiorana; G Bonacorsi; T Artusi; R Trovato; R Marasca; G Torelli
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  Human herpesvirus 6 open reading frame U14 protein and cellular p53 interact with each other and are contained in the virion.

Authors:  Masaya Takemoto; Masato Koike; Yasuko Mori; Sayoko Yonemoto; Yumi Sasamoto; Kazuhiro Kondo; Yasuo Uchiyama; Koichi Yamanishi
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 3.  Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate.

Authors:  J Doniger; S Muralidhar; L J Rosenthal
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

4.  Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene.

Authors:  S Muralidhar; A M Pumfery; M Hassani; M R Sadaie; M Kishishita; J N Brady; J Doniger; P Medveczky; L J Rosenthal
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 5.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Human herpesvirus 6B induces cell cycle arrest concomitant with p53 phosphorylation and accumulation in T cells.

Authors:  Bodil Øster; Bettina Bundgaard; Per Höllsberg
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 7.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 8.  Human herpesvirus 6: An emerging pathogen.

Authors:  G Campadelli-Fiume; P Mirandola; L Menotti
Journal:  Emerg Infect Dis       Date:  1999 May-Jun       Impact factor: 6.883

Review 9.  Chronic viral infection and primary central nervous system malignancy.

Authors:  Robert Saddawi-Konefka; John R Crawford
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-13       Impact factor: 4.147

10.  Direct Repeat 6 from human herpesvirus-6B encodes a nuclear protein that forms a complex with the viral DNA processivity factor p41.

Authors:  Mariane H Schleimann; Janni M L Møller; Emil Kofod-Olsen; Per Höllsberg
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.